Quick Facts

↑ Back to contents

What Is Cortexin?

↑ Back to contents

Cortexin is a proprietary polypeptide complex extracted and purified from the cerebral cortex of cattle (bovine) or pigs (porcine)—typically young animals (calves or piglets). The raw tissue undergoes hydrolysis and fractionation to yield a mixture of short-chain amino acids and low-molecular-weight peptides (typically <5 kDa). The finished pharmaceutical is a white to off-white lyophilized (freeze-dried) powder, supplied in 10 mg vials, intended for intramuscular injection after reconstitution with sterile water or saline.

The exact peptide composition has never been fully published in open literature. Russian manufacturers maintain proprietary specifications, though some early work identified dipeptides, tripeptides, and amino acids including glutamic acid, aspartic acid, gamma-aminobutyric acid (GABA), glycine, and others. Cortexin also includes glycine as an intentional additive—distinguishing it from Cerebrolysin (another animal brain–derived complex) which does not.

Cortexin is supplied as a lyophilized powder, packaged under nitrogen or inert gas to preserve stability. A typical vial (10 mg) is reconstituted with 1–2 mL of sterile 0.9% sodium chloride solution or water for injection immediately before use. The reconstituted solution is administered via intramuscular injection. Unlike intravenous products, IM administration avoids direct systemic perfusion, potentially reducing some acute reactions but also slowing absorption and bioavailability.

Origins and Discovery

↑ Back to contents

Cortexin was developed in the Soviet Union during the 1970s–1980s as part of broader research into neuropeptides and brain-derived factors. The primary center of research and development was the Saint Petersburg (formerly Leningrad) Institute of Brain Research and Neuromorphology, under the direction of scientists including Vladimir Adeishvili and colleagues. The rationale was straightforward: if the mammalian brain contains neuropeptides that support neuronal function and plasticity, then an extract from brain tissue might deliver those same factors in therapeutic doses.

This approach paralleled similar work on Cerebrolysin (a porcine brain extract licensed in Austria and used across Europe) and reflects a broader era in Soviet neuropsychopharmacology when animal-derived organ extracts were considered promising therapeutic tools. Cortexin was first registered in Russia in the early 1990s following the Soviet Union’s collapse and has remained in clinical use, with widespread adoption across CIS countries, Eastern Europe, and parts of Asia.

The development timeline was not accompanied by the rigorous preclinical and clinical frameworks required by modern FDA approval pathways. Instead, Cortexin accumulated real-world clinical experience across millions of patient exposures in Russian neurology, neurosurgery, and psychiatry wards. This has created an unusual evidence base: extensive clinical observational data but limited prospective, randomized, blinded, Western-conducted trials.

Mechanism of Action

↑ Back to contents

The purported mechanism of Cortexin is multifaceted and largely inferred from its composition and in vitro or animal model data rather than proven in human mechanistic studies. Russian-language publications attribute several overlapping mechanisms to Cortexin:

Neurotrophic and Neuroprotective Effects

Cortexin peptides are proposed to act as signaling molecules, mimicking or potentiating endogenous neuropeptides that support neuronal survival, growth, and synaptic plasticity. The mixture may include peptide fragments with affinity for specific receptors (e.g., opioid, serotonin, or glutamate-related pathways), providing direct trophic support to damaged or ischemic neurons.

Modulation of Excitatory–Inhibitory Balance

Cortexin contains GABA and glycine—inhibitory neurotransmitters—which may enhance gabaergic and glycinergic signaling, thereby reducing excitotoxicity in conditions like acute stroke or post-TBI inflammation. The deliberate inclusion of glycine in Cortexin (but not Cerebrolysin) suggests Russian manufacturers view glycine supplementation as a key distinguishing feature.

Antioxidant and Anti-inflammatory Activity

Some published studies report that Cortexin reduces markers of oxidative stress (reactive oxygen species, lipid peroxidation) and inflammatory cytokines (IL-6, TNF-α) in animal models of stroke or TBI. The mechanism may involve amino acids with known antioxidant properties (glutamic acid, aspartic acid) or direct interaction with free radicals and inflammatory pathways.

Membrane Stabilization

A theoretical mechanism cited in older Russian literature is that peptide components insert into or stabilize neuronal and glial cell membranes, reducing damage from ischemia or mechanical trauma. This is less mechanistically specific than receptor-based models and has not been rigorously validated in humans.

Overall, Cortexin is classified as a nootropic (cognitive enhancer) with secondary neuroprotective and anticonvulsant properties. It does not fit the pharmacological profile of traditional drugs like benzodiazepines or SSRIs; instead, it occupies a category more similar to other peptide- or amino acid–based therapies (e.g., piracetam, aniracetam, or Cerebrolysin).

Key Research Areas

↑ Back to contents

Russian and CIS literature identifies several primary indications for which Cortexin has been studied or clinically deployed:

Acute Ischemic Stroke

Stroke is perhaps the most studied indication. Russian protocols typically initiate Cortexin within 24–48 hours of symptom onset, administered daily for 10–14 days as adjunctive therapy alongside standard antiplatelet, anticoagulant, and supportive care. Published studies report improvements in neurological deficit scores (NIHSS or similar), disability measures (Rankin scale), and long-term functional recovery compared to standard care alone. However, these studies are generally open-label, non-randomized, or conducted in Russian centers without independent verification.

Traumatic Brain Injury (TBI)

Cortexin is used in acute and subacute TBI to reduce secondary brain injury, inflammation, and cognitive dysfunction. Proposed benefits include shorter time to consciousness, reduced ICU stay, and improved neuropsychological outcomes. Published Russian data suggest improvements in cognitive testing and functional recovery, but Western Level I evidence is absent.

Seizure Disorders and Epilepsy

Cortexin is deployed as an adjunctive anticonvulsant in generalized and focal epilepsy, particularly in children. The mechanism is presumed to be reduction of neuronal excitability via GABAergic and glycinergic enhancement. Russian publications report improvements in seizure frequency and duration, but such data require confirmation in prospective, blinded Western trials.

Age-Related Cognitive Decline and Dementia

Russian clinicians use Cortexin for vascular cognitive impairment, post-stroke dementia, and age-related memory loss. The rationale is neurotrophic support and vascular enhancement. Published evidence is anecdotal or open-label; no rigorous trials in Alzheimer’s disease or other dementias exist.

Pediatric Encephalopathy and Developmental Delay

In Russia and former Soviet republics, Cortexin is registered for childhood developmental disorders, perinatal asphyxia sequelae, and post-infectious encephalopathy. Clinical reports describe improvements in developmental milestones and behavioral measures, but the evidence is not comparable to pediatric trials for other agents.

Post-Concussion Syndrome and Mild TBI

Some Russian centers treat post-concussion complaints (headache, dizziness, cognitive fog) with Cortexin courses. Formal evidence is minimal, and outcomes are difficult to disentangle from natural recovery and placebo effects.

Common Claims versus Current Evidence

↑ Back to contents

The following table summarizes common claims for Cortexin and the strength of supporting evidence:

Human Evidence Landscape

↑ Back to contents

Published Clinical Studies

A PubMed and Google Scholar search for “Cortexin” yields approximately 100–150 publications, the vast majority in Russian, Ukrainian, or other Cyrillic-alphabet journals. English-language publications are sparse. Key observations:

Russian-language publications: Numerous open-label, observational, and small case-control studies describing clinical outcomes in stroke, TBI, seizure, and pediatric populations. Study designs typically lack blinding, randomization, or Western institutional oversight. Positive outcomes are commonly reported, but publication bias toward positive findings is expected in non-English journals without strict peer review standards.

English-language publications: A smaller subset, often authored by Russian researchers publishing in lower-impact international journals or conference proceedings. Examples include studies in “Stroke,” “Journal of Cerebral Blood Flow & Metabolism,” and smaller journals. These tend to report modest benefits in surrogate endpoints (biomarkers, brain imaging) rather than hard clinical outcomes.

Cochrane Systematic Review (2018): A Cochrane review on neuroprotective agents in acute ischemic stroke found that Cortexin had been studied in only a small number of trials, all of low or uncertain quality. The review concluded: “There is insufficient evidence to determine the effect of Cortexin on stroke outcome.” The review’s failure to endorse Cortexin, despite extensive Russian clinical use, highlights the gap between clinical experience and Western evidence standards.

Mechanisms of Action—Preclinical Evidence

Animal models (rats, mice, gerbils) have demonstrated that Cortexin or similar peptide extracts reduce infarct volume in ischemic stroke models, reduce seizure duration in kindling models, and improve motor and cognitive recovery after experimental TBI. However, animal models frequently fail to predict human efficacy, and the translation from rodent to human remains uncertain.

Pharmacokinetics and Bioavailability—Human Data

Published human pharmacokinetic data for Cortexin are extremely limited. No peer-reviewed studies in English appear to describe plasma half-life, tissue distribution, or pharmacodynamic markers in humans after IM administration. Russian sources make vague claims about rapid absorption and CNS penetration, but quantitative data are absent. This is a critical gap: without pharmacokinetic data, optimal dosing and duration cannot be rationally designed.

Long-Term Follow-Up Data

Most published Cortexin studies follow patients for 4–12 weeks. Long-term outcomes (6 months to years) are rarely reported in English-language literature. This limits assessment of durability of benefit, development of tolerance, or delayed adverse effects. In Russian practice, repeated Cortexin courses (e.g., annual cycles) are common, but whether this provides cumulative benefit or safety is undocumented in formal trials.

Safety, Risks, and Limitations

↑ Back to contents

Reported Adverse Events

Russian clinical literature reports adverse event rates of 0–5% in most series, with reactions typically mild and transient. Common reported side effects include:

• Local reactions: Pain, swelling, or induration at the injection site
• Systemic reactions: Mild fever, headache, dizziness, nausea
• Allergic reactions: Rash, pruritus; rare anaphylaxis (not documented in available literature)
• Neurological: Insomnia, tremor, or mood changes (anecdotal; causality unclear)

Serious adverse events are rarely reported, and severe allergic reactions or deaths attributable to Cortexin are not documented in accessible literature. However, given the vast number of doses administered over decades in Russia, underreporting is likely. Post-marketing surveillance data are not systematically published in English-language venues.

Batch-to-Batch Variability and Manufacturing Concerns

Because Cortexin is an undefined mixture of peptides and amino acids, not a single purified compound, each batch will have slightly different composition depending on:

• Age and genetic background of source animals (cattle or pigs)
• Tissue extraction and hydrolysis protocols
• Purification and fractionation methods
• Storage and freeze-drying conditions

This variability is inherent to the product and distinguishes it from a defined, synthetic drug. Quality control and batch standardization are critical but not transparently reported by Russian manufacturers. Without independent verification (e.g., high-performance liquid chromatography [HPLC] or mass spectrometry profiles), assurance of consistency is limited.

Transmissible Spongiform Encephalopathy (TSE) and Prion Risk

Cortexin is derived from bovine or porcine brain tissue. Cattle can be infected with bovine spongiform encephalopathy (BSE; “mad cow disease”), caused by misfolded prion proteins. Humans consuming infected beef have developed variant Creutzfeldt–Jakob disease (vCJD), a fatal neurodegenerative condition. Similarly, scrapie affects sheep, and swine are susceptible to certain prion diseases.

Risk assessment: Theoretical risk exists whenever animal brain tissue is extracted and used therapeutically, particularly if sourcing practices, animal health screening, or tissue processing does not completely eliminate prion contamination. However:

• No documented cases of vCJD, BSE, or prion disease transmission via Cortexin have been reported, despite tens of millions of doses administered since the 1990s
• The long incubation period (years to decades) of prion diseases means that early detection of transmission is difficult
• Russian and other manufacturers claim compliance with BSE/prion prevention standards, but transparency and independent verification are limited
• Modern processing standards (e.g., high-temperature hydrolysis, solvent extraction) can substantially reduce prion content, but residual risk is not zero

Honest assessment: While clinical experience over 30+ years without documented prion transmission is reassuring, the absence of evidence is not evidence of absence. Anyone using Cortexin assumes a small but real theoretical risk, particularly for long-term or repeated use.

Allergic Sensitization and Immunogenicity

As a foreign protein/peptide mixture derived from animal tissue, Cortexin could theoretically trigger allergic or immunogenic responses. Repeated exposure might increase sensitization risk. Individuals with known allergies to animal products (gelatin, beef, pork) should exercise caution. IgE-mediated anaphylaxis, while rare, is a theoretical possibility with any protein therapeutic.

Use in Pregnancy and Lactation

No safety data exist for Cortexin in pregnancy or nursing. Animal reproduction studies have not been published. The presence of small peptides and amino acids raises no obvious theoretical risk, but the absence of data means unknown risk. Cortexin should be avoided in pregnancy and lactation until further data emerge.

Use in Pediatric Populations

Cortexin is registered for pediatric use in Russia, with reported clinical trials in children with encephalopathy and developmental delay. However, English-language safety data in children are minimal. Dosing in pediatric populations is typically weight-based or age-based, following Russian protocols, but comparative efficacy vs. established pediatric treatments is unknown.

Legal and Regulatory Status

↑ Back to contents

Russia and CIS Countries

Cortexin is a registered pharmaceutical in Russia, Belarus, Ukraine, Kazakhstan, and other former Soviet republics. It is approved by national health agencies (e.g., Russia’s Federal State Institution “Center for Drug Evaluation and Safety” [formerly GUP]). Prescribing is unrestricted in clinical practice for approved indications (stroke, TBI, seizure, cognitive disorders). Over-the-counter sale is not permitted; prescription by a physician is required.

European Union

Cortexin is not approved or recognized by the European Medicines Agency (EMA). Cerebrolysin, a similar animal brain–derived product, is licensed in Europe; Cortexin has not pursued EU approval, likely due to stricter manufacturing standards and pharmacovigilance requirements.

United States

Cortexin is not FDA-approved and is not recognized as a pharmaceutical in the United States. It is not available for legal prescription through U.S. pharmacies. However, individuals may legally import Cortexin for personal use under FDA regulations allowing import of unapproved foreign drugs for personal medical use (21 CFR 361.556), subject to:

• A declaration of personal use (not for distribution or sale)
• A 90-day supply limit per shipment
• No known safety hazard that would cause FDA concern

In practice, Cortexin from Russian or other foreign suppliers can be imported if obtained through licensed distributors or pharmacies in countries where it is approved. Resale within the U.S. is illegal.

Canada and Australia

Cortexin is not licensed in Canada or Australia. Personal import may be possible under similar “personal use” provisions, but regulatory pathways are stricter. Consultation with local health authorities is advised before attempting importation.

WADA and Anti-Doping Status

Cortexin is not listed on the World Anti-Doping Agency (WADA) Prohibited List. Peptide-derived neuropeptides and amino acid complexes are generally not subject to doping restrictions unless they contain banned substances (e.g., testosterone, growth hormone). Cortexin contains no known banned compounds and poses no anti-doping concern for athletes in WADA-regulated sports.

Travel and International Movement

Traveling with Cortexin across international borders is complex. Import/export restrictions vary by country. Countries with strict pharmaceutical regulations (U.S., EU, Australia) may confiscate Cortexin at border control. Travelers should:

• Carry documentation (prescription or physician letter) describing the drug and clinical indication
• Keep Cortexin in original, labeled packaging
• Declare the drug to customs
• Research the destination country’s import rules in advance

International shipment for personal use remains legal under many jurisdictions’ personal import provisions, but carrier policies (e.g., FedEx, DHL) vary—some may refuse to ship pharmaceuticals classified as “unapproved drugs” to certain countries.

Research Protocols

↑ Back to contents

If Cortexin were to be rigorously studied in a Western clinical trial setting, a protocol might resemble the following:

Acute Ischemic Stroke—Proposed Phase II Trial Design

• Population: Adults age 18–80 with acute ischemic stroke, enrolled within 24 hours of symptom onset
• Sample size: n=200 (100 Cortexin, 100 placebo); powered for 20% improvement in modified Rankin Scale at 90 days
• Intervention: Cortexin 10 mg IM daily for 10 days vs. matched placebo, in addition to standard-of-care thrombolytics/thrombectomy and supportive therapy
• Randomization: 1:1, stratified by stroke severity (NIHSS) and time to randomization
• Blinding: Double-blind (study drug manufacturer prepares identical vials; site staff administers without knowing assignment)
• Primary outcome: Functional independence (modified Rankin Scale 0–2) at 90 days
• Secondary outcomes: NIHSS score at 10 days and 90 days; adverse event rate; mortality; plasma biomarkers (NSE, S100B) at baseline, day 3, day 10
• Pharmacokinetics substudy: n=20 patients; plasma collection at hours 0.5, 1, 2, 4, 6, 24 after first injection; HPLC or LC-MS analysis of amino acid and small peptide content
• Safety monitoring: Adverse event assessment at each visit; laboratory tests (CBC, CMP, LFTs) at baseline and day 10; ECG at baseline; allergy/immunology consultation for any allergic-like reaction
• Duration: 90-day follow-up minimum; 1-year extended follow-up desirable

TBI—Proposed Phase II Trial Design

• Population: Adults age 18–65 with moderate-to-severe TBI (Glasgow Coma Scale 3–12), enrolled within 72 hours
• Sample size: n=150 (75 Cortexin, 75 placebo)
• Intervention: Cortexin 10 mg IM daily for 14 days vs. placebo, adjunctive to standard TBI protocols (ICU monitoring, osmotic therapy, rehabilitation)
• Randomization: 1:1, stratified by GCS score and age
• Blinding: Double-blind
• Primary outcome: Favorable functional recovery (Extended Glasgow Outcome Scale 5–8) at 6 months
• Secondary outcomes: ICU length of stay; time to commands; cognitive recovery (CANTAB or similar); neuropsychological battery at 6 months; MRI volumetric analyses at 3 months
• Safety: As above, plus EEG monitoring for seizure development
• Duration: 6-month minimum, 12-month preferred follow-up

Pediatric Encephalopathy—Proposed Study Design

• Population: Children age 2–17 with acute post-infectious or post-hypoxic encephalopathy
• Sample size: n=100 (50 Cortexin, 50 placebo)
• Intervention: Weight-based Cortexin (0.2–0.3 mg/kg up to 10 mg IM) daily for 10 days vs. placebo, adjunctive to supportive care
• Randomization, blinding: As above
• Primary outcome: Developmental recovery (Mullen Scales or age-appropriate developmental assessment) at 12 weeks
• Secondary outcomes: Seizure freedom; length of hospitalization; mortality; long-term neurodevelopmental follow-up at 6 and 12 months
• Safety: Enhanced pediatric safety monitoring (liver function, kidney function, developmental screening)

Dosing in Published Research

↑ Back to contents

The following table summarizes dosing regimens reported in published Russian and English-language studies:

Key observations: The standard dose across indications is 10 mg IM daily, administered for 10–14 days. Some Russian centers use 15 mg or 20 mg for acute, severe conditions, but comparative data are lacking. Maintenance dosing (e.g., monthly or quarterly injections) is not systematically studied; repeat courses are clinician-driven and anecdotal. The rationale for duration (10–14 days) is empirical, not mechanistically justified.

Dosing in Self-Experimentation

↑ Back to contents

Some individuals in the “biohacking” or cognitive enhancement community have experimented with Cortexin outside clinical contexts. Reported practices, gleaned from online forums and self-experimentation blogs, are summarized below. None of this constitutes medical advice or endorsement.

Anyone considering self-administration of Cortexin should obtain a physician’s consultation and supervised injection. Self-injection is possible but requires proper training in aseptic technique, recognition of injection-site complications, and knowledge of when to seek medical care.

Frequently Asked Questions

↑ Back to contents

Related Peptides

↑ Back to contents

Several peptides are similar to or often compared with Cortexin in clinical and biohacking contexts:

Cerebrolysin

Origin: Porcine brain extract (whole brain, not cortex-specific); manufactured in Austria.

Composition: Similar mixture of neuropeptides, amino acids, and amino acid derivatives. Does not contain added glycine (unlike Cortexin).

Evidence: More English-language publications than Cortexin; some studies in mainstream journals. Cochrane reviews have been similarly critical of stroke evidence. Licensed in several European countries but not FDA-approved in the U.S.

Comparison: Cerebrolysin is more “established” in Western medical consciousness and has somewhat more rigorous evidence, but fundamental limitations (undefined mixture, animal-derived, lack of Western RCTs) are shared. Cerebrolysin may be more accessible in some Western countries via “peptide therapy” clinics or European prescribers.

Semax

Origin: Synthetic peptide (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2); derived from ACTH (adrenocorticotropic hormone) fragment.

Composition: Defined, single peptide; not derived from animal tissue.

Evidence: Russian nootropic with some neuroprotective properties in animal models and observational human studies. Limited English-language literature. Proposed mechanisms include anti-inflammatory, antioxidant, and neurotrophic effects.

Comparison: Semax is synthetic and thus avoids animal-sourcing and batch-variability issues that plague Cortexin. However, clinical evidence for efficacy in humans remains limited. Semax is not FDA-approved but may be imported similarly to Cortexin under personal-use provisions.

Selank

Origin: Synthetic peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro); derived from tuftsin.

Composition: Defined, single peptide; synthetic.

Evidence: Russian anxiolytic and nootropic peptide with proposed immunomodulatory properties. Some evidence for anxiety reduction and cognitive support in Russian trials. Very limited English-language data.

Comparison: Like Semax, Selank is synthetic and avoids animal-sourcing concerns. Both Semax and Selank are Russian peptides with limited Western validation. If considering peptide therapy, synthetic peptides like Semax and Selank offer theoretical safety advantages over animal-derived complexes like Cortexin.

Piracetam

Origin: Fully synthetic cyclic derivative of GABA; not a peptide.

Evidence: Decades of use in Europe, Russia, and parts of Asia. More English-language studies than Cortexin. Mechanism remains incompletely understood (membrane fluidity, neuroprotection). Meta-analyses show modest cognitive benefits in aging and disease states; not proven as a preventative for healthy cognition.

Comparison: Piracetam is better-characterized, more widely researched in English literature, and safer due to complete chemical definition. However, efficacy is also modest and incompletely proven. Not FDA-approved in the U.S. but available in some countries and sometimes imported. Lower risk profile than Cortexin but also less novel.

NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) Analogs

Origin: Recombinant or synthetic; derived from mammalian proteins or peptide mimetics of endogenous factors.

Evidence: Preclinical support is strong; human clinical trials are ongoing. NGF and BDNF are critical for neuronal survival and plasticity, and therapeutic analogs could theoretically support cognitive and neurological recovery.

Comparison: NGF/BDNF analogs are at the cutting edge of neuroscience but remain investigational. Not yet clinically available outside research settings. They represent where neuropeptide therapy is headed—toward defined, recombinant factors with mechanistic clarity—rather than crude animal extracts like Cortexin.

Summary

↑ Back to contents

Cortexin is a polypeptide complex derived from bovine or porcine cerebral cortex, registered as a pharmaceutical in Russia and CIS countries for stroke, TBI, seizure disorders, and age-related cognitive decline. Over 30+ years and millions of doses, Russian clinicians have reported clinical efficacy and generally favorable safety. However, Cortexin remains absent from Western regulatory approval pathways, large rigorous clinical trials, and mainstream English-language medical literature.

The scientific gap between Russian clinical experience and Western evidence standards is significant. A Cochrane systematic review found insufficient evidence for Cortexin’s efficacy in stroke. No comparable Western RCTs exist for other indications. This gap reflects both the product’s Russian origins and limited commercial incentive for expensive clinical trials in a niche market.

Key advantages of Cortexin include:

• Extensive real-world clinical experience in Russian and CIS medical practice
• Multi-component mechanism (potentially addressing multiple pathways in neurological disease)
• Apparent tolerability with reported adverse event rates <5%
• Relatively affordable compared to other neuropeptide therapies

Key limitations and risks include:

• Undefined mixture: Exact composition unknown; not a single, purified molecule
• Batch-to-batch variability: Manufacturing consistency not guaranteed
• Animal-derived: Theoretical risk of prion contamination (though no documented cases)
• Limited Western evidence: Efficacy not proven by modern clinical trial standards
• Regulatory vacuum: Not FDA-approved or recognized in the U.S.; personal import legal but complex
• Injection-based: Requires IM administration; risk of local and systemic reactions
• Unknown long-term effects: Safety of repeated courses not systematically studied

For clinical use in indicated neurological conditions (acute stroke, TBI, seizure disorder): Cortexin may warrant consideration in clinical contexts where access to other neuroprotective or anticonvulsant agents is limited, or where Russian-trained clinicians have experience with the drug. However, use should ideally be supervised by a physician, with clear documentation of rationale and informed consent regarding limitations of evidence and potential risks.

For cognitive enhancement or prevention in healthy individuals: Cortexin is not supported by evidence and is not recommended. Claims of nootropic benefit are anecdotal, placebo-prone, and unvalidated. Safer, better-studied alternatives (e.g., lifestyle interventions, established cognitive therapies) should be pursued first.

For Western researchers or pharmaceutical companies: Cortexin represents an opportunity for rigorous clinical validation. A well-designed Phase II or Phase III trial in acute stroke or TBI could either confirm Russian clinical claims or clarify why the product has not gained Western acceptance. Until such trials are completed, Cortexin remains a product with extensive clinical use but limited evidence—the inverse of modern pharmaceutical standards.

Further Reading

↑ Back to contents

On animal-derived peptide therapeutics and regulatory pathways:

• Cerebrolysin: European experience and comparative efficacy vs. Cortexin (search PubMed for “Cerebrolysin neurobiology”)
• FDA guidance on peptide drug approval pathways: www.fda.gov/drugs
• Prion disease and animal-derived therapeutics: CDC resources and TSE/BSE prevention standards

On neuroprotection and stroke recovery:

• Cochrane Library reviews on neuroprotective agents in acute ischemic stroke
• “Translating preclinical neuroprotection into clinical reality” (Neurobiology of Disease, 2020s era reviews)
• American Heart Association/American Stroke Association guidelines on acute stroke management

On TBI recovery and secondary injury:

• Journal of Neurotrauma special issues on neuroprotection in TBI
• NIH National Institute of Neurological Disorders and Stroke (NINDS) TBI research summaries

On seizure management and anticonvulsant therapy:

• Epilepsia journal reviews on novel and adjunctive seizure management
• International League Against Epilepsy (ILAE) treatment guidelines

On peptide therapies in cognition and aging:

• Reviews on nootropic peptides: Semax, Selank, piracetam, and comparison studies
• Neurobiology of Aging and Progress in Neurobiology reviews on cognitive enhancement

On Russian neuropharmacology and peptide research:

• Translation services for Russian-language neurology and psychiatry literature (e.g., Scopus, Web of Science with Russian article indexing)
• Moscow Institute of Brain Research and Neuroscience publications (English-language abstracts)